Diurnal Limited

Pfizer Corporation

Church Dwight & Co., Inc.

D3 Pharma Limited

Hiep Huatan

Richard Ross

Hengmiao Cheng

Peter Bertinato

Brian S Bronk

Jin Li

Alan Elwood Blize

Martin Whitaker

Clive Mason

Caryn Culleton Oryniak

Luis C Muniz

Lindsey Bagley

Ovidiu Romanoschi

Graham Godfrey

Nazim Kanji

Huw Jones

Caryn Oryniak

Norbert Poellinger

Annette Grave

The present disclosure provides oral, chewable dosage forms that are suitable for delivery of one or more active ingredients to a consumer, particularly a human individual. The dosage forms can be configured as multicomponent compositions formed of a first component including a gummy composition, at least one further component including a composition that is different from the gummy composition, and an active ingredient. The gummy composition and the second composition can be co-deposited to form multicomponent dosage forms wherein a gummy shell at least partially surrounds a core that is solid or liquid at standard temperature.

Multicomponent gummy compositions with soft core

The present disclosure provides oral, chewable dosage forms that are suitable for delivery of one or more active ingredients to a consumer, particularly a human individual. The dosage forms can be configured as multicomponent compositions formed of: a first component including a gummy composition; a second component that is a particulate material or is a pre-formed solid unit or plurality of pre-formed solid units; and an active ingredient. The second component can be, for example, in the form of a pharmaceutically acceptable oral dosage unit, such as a tablet, a caplet, a soft shell capsule, a hard shell capsule, a microcapsule, or a pastille.

Multicomponent gummy compositions with hard core

The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.

Hydrocortisone controlled release formulation

The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to pediatric treatment regimens, the treatment of the elderly and non-human animals.

Treatment of adrenal insufficiency

The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

Composition comprising hydrocortisone

We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm.

Lipid composition

The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R-Rare as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

Triamide-substituted heterobicyclic compounds

The invention relates to triamide MTP/ApoB inhibitors of the formula 1wherein R-Rare as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

Growing community of inventors

Maidstone, United Kingdom

Hiep Huatan